Brief: Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals

17/12/2020 14:24

Dec 17 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPION DEMONSTRATES SAFETY IN COVID-19 PATIENTS AND
INITIATES
GLOBAL CLINICAL TRIAL FOR INTRAVENOUS AMPION
    * AMPIO PHARMACEUTICALS INC - SAFETY MONITORING COMMITTEE
FOUND IV
TREATMENT OF AMPION TO BE SAFE AND WELL-TOLERATED FOR 90-DAYS
    * AMPIO PHARMACEUTICALS - STUDY MET PRIMARY SAFETY ENDPOINT
AFTER
5 DAYS OF IV AMPION TREATMENT AND AGAIN AFTER 3 MONTHS
    * AMPIO - STUDY SHOWED PROMISING EFFICACY WITH IV AMPION
TREATMENT
GROUP SEEING STRONGER CLINICAL IMPROVEMENT THAN STANDARD OF CARE
GROUP

Source text for Eikon:  ID:nPn62yj2ha 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))